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Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel 
disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve 
IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD 
subgroups, and treatment outcomes.
Patients and methods: Fecal samples were collected from 235 children below 18 years of 
age. Eighty children had Crohn’s disease (CD), 27 ulcerative colitis (UC), 3 IBD unclassified, 
50 were non-IBD symptomatic patients, and 75 were healthy. The bacterial abundance of 54 
predefined DNA markers was measured with a 16S rRNA DNA-based test using GA-Map™ 
technology at diagnosis and after therapy in IBD patients.
Results: Bacterial abundance was similarly reduced in IBD and non-IBD patients in 51 of 
54 markers compared to healthy patients (P<0.001). Only Prevotella was more abundant 
in patients (P<0.01). IBD patients with ileocolitis or total colitis had more Ruminococcus 
gnavus (P=0.02) than patients with colonic CD or left-sided UC. CD patients with upper 
gastrointestinal manifestations had higher Veillonella abundance (P<0.01). IBD patients 
(58%) who received biologic therapy had lower baseline Firmicutes and Mycoplasma hominis 
abundance (P<0.01) than conventionally treated. High Proteobacteria abundance was associ-
ated with stricturing/penetrating CD, surgery (P<0.01), and nonmucosal healing (P<0.03). 
Low Faecalibacterium prausnitzii abundance was associated with prior antibiotic therapy 
(P=0.001), surgery (P=0.02), and nonmucosal healing (P<0.03). After therapy, IBD patients 
had unchanged dysbiosis.
Conclusion: Fecal microbiota profiles differentiated IBD and non-IBD symptomatic children 
from healthy children, but displayed similar dysbiosis in IBD and non-IBD symptomatic patients. 
Pretreatment fecal microbiota profiles may be of prognostic value and aid in treatment individu-
alization in pediatric IBD as severe dysbiosis was associated with an extensive, complicated 
phenotype, biologic therapy, and nonmucosal healing. The dysbiosis persisted after therapy, 
regardless of treatments and mucosal healing.
Keywords: dysbiosis, Crohn’s disease, ulcerative colitis, Proteobacteria, biologic therapy, 
Faecalibacterium prausnitzii
Plain language summary
•	 Studies have shown a disturbed gut bacterial composition in chronic inflammatory diseases 
such as inflammatory bowel disease (IBD) (Crohn’s disease and ulcerative colitis).
•	 In children, it might be difficult to diagnose IBD. Symptoms are often nonspecific, such as 
abdominal pain and altered bowel movements.
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•	 Dr Olbjørn et al investigated whether the bacterial composi-
tion from stool samples can help to diagnose and treat IBD in 
children.
•	 They used advanced DNA profiling to identify and quantify 
bacteria. They compared the bacterial composition in stool 
from children with IBD with healthy children and children with 
gastrointestinal symptoms but without inflammation.
•	 The researchers report that the bacterial composition in patients 
with IBD was very different than in healthy children. The dif-
ferences persisted after treatment.
•	 The bacterial composition in patients with gastrointestinal 
symptoms but no inflammation was similarly disturbed as in 
IBD patients.
•	 The degree of disturbances in the bacterial composition in 
children with IBD correlated with the disease course and later 
therapy. Patients with higher numbers of “bad” bacteria, such as 
Proteobacteria, were more likely to need aggressive treatment 
and surgery.
•	 In children with IBD, testing the bacterial composition in the 
stool before treatment can help physicians in targeting and 
individualizing treatments.
Introduction
The pathogenesis of the inflammatory bowel diseases (IBD), 
Crohn’s disease (CD), and ulcerative colitis (UC) is not fully 
understood, but IBD is thought to occur due to an exagger-
ated immune response to luminal microbial contents in the 
gastrointestinal tract in genetically susceptible individu-
als.1 A rising incidence of IBD, especially in the pediatric 
population, has been demonstrated, and the influence of 
environmental changes, including diet and gut microbiota 
on the disease pathogenesis, is increasingly recognized.2,3 
The gut microbiota is thought to play an important role not 
only in IBD but also in functional gastrointestinal disorders 
such as irritable bowel syndrome, which may display similar 
symptoms representing a differential diagnosis to IBD.4,5 
Studies of the gut microbiota in IBD and functional gas-
trointestinal disorders have shown an imbalance, dysbiosis, 
with compositional changes, including decreased bacterial 
diversity and abundance.6–8 The shift in the gut microbiota 
seems to be associated with a depletion of beneficial vs 
a relative increase of pro-inflammatory bacteria.9,10 The 
diagnostic and  prognostic significance of fecal microbiota 
profiles in children with gastrointestinal symptoms and IBD 
is not fully explored.
We hypothesized that the fecal microbiota composition 
could be helpful in diagnosing pediatric IBD patients and in 
predicting their prognosis. We aimed to assess differences 
in the abundance of fecal microbiota in treatment-naïve 
 pediatric IBD patients at the time of diagnosis compared to 
healthy controls and pediatric non-IBD patients with gastro-
intestinal symptoms. We further explored the value of micro-
biota abundance in differentiating between IBD phenotypes, 
subsequent need of biologic therapy, surgery and treatment 
outcomes, and whether the microbiota changes with therapy.
Patients and methods
IBD patients, non-IBD symptomatic 
patients, and healthy controls
Patients enrolled in the present study were recruited from 
the catchment areas of two university hospitals in three 
population-based prospective epidemiological studies of 
treatment-naïve pediatric IBD in South-Eastern Norway 
(IBSEN II),11,12 Early IBD (in preparation), and EU IBD 
Character.13 The inclusion periods for these three multicenter 
trials were from 2005 to 2015, all with identical protocols and 
inclusion criteria. Pediatric patients under 18 years, referred 
during the inclusion periods and believed to have IBD based 
on symptoms, were included. IBD was diagnosed in accor-
dance with the Porto criteria.14 Patients who did not meet 
the diagnostic criteria for IBD were included as non-IBD 
symptomatic controls. These patients had a macroscopically 
and histologicallly normal mucosa and normal MRI examina-
tions. Healthy children and adolescents between the age of 2 
and 18 years and recruited during the period of 2013–2014 
from the same catchment areas as the patients delivered 
fecal samples and were included as healthy controls. They 
had no chronic diseases, no IBD in the family, followed a 
normal diet (children on exclusion diets, gluten-free, cows 
milk protein-free, vegetarian/vegan, were excluded), had not 
traveled outside Europe or used antibiotics within the last 6 
months, had no recorded gastrointestinal complaints, did not 
use proton pump inhibitors, and had normal fecal calprotectin 
levels (<50 mg/kg).15
Clinical, endoscopic, radiological, and 
laboratory data
Age, gender, symptoms, disease activity index scores, dis-
ease, and family history of the IBD and non-IBD symptom-
atic patients were registered as previously described.11,12,16 The 
Paris classification was used to characterize disease distribu-
tion and behavior.17 In patients, feces were sampled at home 
in three designated containers without additives on the day 
before endoscopy, kept refrigerated or frozen, and brought 
to the hospital the next day. Fecal sample from one container 
was analyzed for calprotectin (FeCal-test, Bühlmann, Basel, 
Switzerland), the second for pathogenic bacteria, and the third 
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container with feces was frozen at –80°C for later microbiota 
analysis. The healthy controls received two designated fecal 
sampling kits at home for handling of samples before deliv-
erance to Genetic Analysis AS, Oslo, Norway. One sample 
was analyzed for fecal calprotectin (FeCal-test, Bühlmann); 
the other was frozen at –80°C and stored for later microbiota 
analysis. For all samples, the maximum time interval until 
frozen at –80°C was 3 days; thereafter the samples were kept 
frozen and not thawed until analysis.
Microbiota analysis
The microbiota was analyzed using the GA-Map™ technol-
ogy (Genetic Analysis AS), a PCR, and 16S RNA-based 
analysis. The method uses a targeted approach to detect 
predefined bacteria believed to be important in identifying 
and characterizing gut bacteria dysbiosis.18 The test measures 
relative bacterial abundance based on the fluorescence signal 
strength (FSS) of bacterial DNA markers. The markers are 
targeting variable regions V3–V7 of the bacterial 16S rRNA 
gene. The method utilizes 54 bacterial markers (Table S1), 
covering more than 300 bacteria at different taxonomic levels: 
26 species specific, 19 detect genus specific, and 9 bacteria 
at higher taxonomic levels (phyla, class, and family). All 
samples were analyzed at the same time point. The laboratory 
was blinded for the diagnosis of IBD, non-IBD, or healthy.
iBD treatment
Treatment was decided individually, prospectively, at the dis-
cretion of the treating pediatrician. Initial treatment options 
to induce remission were exclusive enteral nutrition in CD 
and corticosteroids and/or 5-aminosalicylic acids in CD 
and UC patients. Maintenance therapy with azathioprine or 
methotrexate was in general started simultaneously (Table 1). 
The indication for surgery or treatment with biologic therapy 
(TNF blockers) was failure to induce remission with conven-
tional treatments or relapse after primary induction.
statistical analyses
Data were described using counts and percentages for cat-
egorical data and medians and ranges for continuous data. To 
explore the ability of all 54 bacterial markers to distinguish 
between IBD, non-IBD symptomatic patients, and healthy 
controls, we performed principal component analysis. The 
FSSs from the 54 markers were added for each patient, 
and the sum illustrated a relative abundance, denoted the 
total signal strength. Crude comparisons between groups 
were  performed using Mann–Whitney Wilcoxon tests and 
 Wilcoxon signed-rank tests (before and after treatment) for 
continuous variables and chi-squared tests for categorical 
data.
Areas under the curves were calculated and receiver 
operating characteristic analysis conducted to evaluate the 
performance of selected bacterial abundances in distinguish-
ing IBD phenotypes and treatments. All tests were two-sided. 
P-values <0.05 were considered statistically significant. We 
regarded our study exploratory; therefore, we did not correct 
for multiple testing. However, in order to validate our results, 
each observation was randomized into a test set or a training 
set so that the number of observations was equal in both sets. 
Only the statistically significant differences confirmed in the 
training set are reported. All analyses were performed using 
SPSS, statistical software, version 24 (SPSS Inc., Chicago, 
IL, USA) and Stata, version 9.
Ethical considerations
The study was conducted with informed patients and parental/
guardian written consent as appropriate and with full ethical 
approval, in accordance with the Declaration of Helsinki, 
and with approval by the Regional Committee for Medical 
Research Ethics, South-Eastern Norway, reference no. REK 
S-04209.
Table 1 Disease extent and behavior at diagnosis according to 
the Paris classification and treatments in pediatric IBD patients
IBD diagnosis n (%)
CD 80 (73)
UC 27 (25)
iBDU 3 (3)
CD behavior  
Inflammatory 53 (66)
stricturing 12 (15)
Penetrating 15 (19)
CD distribution  
ileal 5 (6)
Colonic 24 (30)
ileocolonic 47 (59)
Upper gastrointestinal 54 (68)
Perianal 17 (21)
UC/IBDU disease extent  
Proctitis 5 (17)
left sided colitis 8 (27)
Extensive/total colitis 17 (57)
Treatment  
immunomodulators 98 (89)
Biologic therapy 64 (58)
surgery 17 (15)
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, 
inflammatory bowel disease unclassified; UC, ulcerative colitis.
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Results
Of the 235 included children and adolescents, IBD was 
diagnosed in 110 patients (80 CD, 27 UC, and 3 IBDU) 
(Table 1), 50 patients were included as non-IBD symptomatic 
patients, and 75 healthy children served as controls. None of 
the non-IBD symptomatic patients have developed IBD as of 
December 1, 2018. IBD, non-IBD, and healthy controls were 
comparable concerning all demographic variables except for 
more females among the non-IBD patients and a slightly 
lower median age in the healthy controls (Table 2).
The bacterial abundances were compared between the three 
pediatric groups, healthy controls, IBD patients and non-IBD 
symptomatic patients, as well as between subgroups of IBD 
and after treatment in 31 of the IBD patients. To investigate the 
impact of antibiotics on microbiota profiles of the IBD patients, 
they were grouped according to whether they had received anti-
biotics within 3 months prior to diagnosis or not, and analyzed 
Figure 1 Faecalibacterium prausnitzii abundance in IBD patients according to whether they had received antibiotics prior to the diagnosis (measured in fluorescence signal 
strength in 1,000 units).
Abbreviation: IBD, inflammatory bowel disease.
P=0.001
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Table 2 Demographics and laboratory tests of IBD, non-IBD patients, and healthy controls at baseline
Variable CD UC IBD (CD +  
UC + IBDU)
Non-IBD Healthy
Patients, n (%) 80 (100) 27 (100) 110 (100) 50 (100) 75 (100)
age in years, median (range) 13 (0.74–17.9) 11.5 (4–17) 12.5 (0.74–17.9) 12 (3.7–18) 10 (2–17.9)
Males, n (%) 43 (54) 11 (41) 56 (51) 18 (36) 34 (45)
PCDai/PUCai, median (range) 20 (0–62.5) 40 (0–75) – n/a n/a
Fecal calprotectin mg/kg, median (range) 589 (20–8,625) 987 (11–6,123) 701 47 (9–1,260) 15 (0–50)
Fecal calprotectin
>1,000 mg/kg, n (%)
31 (39) 12 (48) 43 (40) 2 (4) 0
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease unclassified; N/A, not applicable; PCDAI, pediatric Crohn’s 
disease activity index; PUCai, pediatric ulcerative colitis activity index; UC, ulcerative colitis.
separately. Eight of the 110 IBD patients had received anti-
biotics, and these patients had significantly lower abundance 
of Faecalibacterium prausnitzii (P=0.001) compared to IBD 
patients without prior antibiotic therapy (Figure 1). However, 
excluding these patients from the statistical analyses did not 
impact the other results presented in the material.
Microbiota in relation to age
We found significant differences in microbiota abundance 
when comparing healthy children below (n=38) and above 
(n=37) 10 years of age. Healthy children aged <10 years had 
lower abundance of Clostridiales and higher abundance of 
Bifidobacterium, both P<0.01. These differences were not 
replicated in the patients as we did not find any differences 
in bacterial profiles between high and low age groups in the 
IBD and non-IBD symptomatic patient groups. Additional 
post hoc analysis with an age matched selection of controls 
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did not influence outcome/differences between patients and 
healthy.
Microbiota in IBD and non-IBD vs healthy
In all symptomatic patients, regardless of IBD or non-IBD 
status, the total signal strength, measured as the sum of the 
54 FSSs, was significantly lower compared to healthy con-
trols, illustrating that the patients had lower abundance of 
the predefined bacterial markers. Patients had reduced bac-
terial abundances in 51/54 markers, P<0.001 (Figure 2). The 
only bacterial marker that was more abundant in patients 
(IBD and non-IBD) compared to healthy controls was 
Prevotella (P<0.01). The abundances of Lachnospiraceae 
and Bacteroides were similar in all groups. The principal 
component analysis plot visualizes how the microbiota 
composition differs between IBD, non-IBD, and healthy 
and overlaps between IBD and non-IBD symptomatic 
patients (Figure 3).
Microbiota in IBD vs non-IBD
The bacterial abundances were similarly dysbiotic in IBD and 
non-IBD symptomatic patients; however, one marker target-
ing the Firmicutes phylum was significantly less abundant 
in IBD patients compared to non-IBD patients (P<0.01), as 
well as Eubacterium rectale (P<0.01), Eubacterium biforme/
Streptococcus agalactiae (P=0.04), Parabacteroides, and 
Bifidobacterium species (both P=0.02).
Microbiota in iBD patients
The fecal microbiota abundances did not differ between UC 
and CD, except that CD patients had lower abundance of 
Mycoplasma hominis (P<0.02).
Microbiota related to disease distribution and 
behavior in iBD patients
IBD patients with extensive disease, ileocolitis in CD or 
extensive colitis in UC, had higher abundance of Rumi-
nococcus gnavus (P=0.02) compared to CD patients with 
isolated colonic disease and UC patients with limited disease 
distribution (left-sided colitis or proctitis). CD patients with 
upper gastrointestinal involvement had higher Veillonella 
abundance (P<0.01) compared to patients without upper 
gastrointestinal lesions.
CD patients with a high abundance of Proteobacteria were 
more likely to have complicated disease behavior, stricturing 
or penetrating disease, compared to patients with lower levels 
of these bacteria, P<0.01 (Figure 4).
Microbiota and association with treatment
IBD patients who were treated with biologic therapy, 64 
(58%), had lower abundance of Firmicutes (P=0.015) and 
M. hominis (P=0.009) compared to conventional treated 
patients (Figure 5). Seventeen (15%) of the IBD patients 
required surgery, and mucosal healing (assessed by ileo-
colonoscopy) was not achieved in 40 (36%) of the patients 
Figure 2 Boxplot illustrating the differences in the total fluorescence signal strength measured in 1,000 units between IBD, non-IBD symptomatic patients, and healthy 
controls.
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified; ns, not significant.
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despite medical therapy. Surgery and lack of mucosal healing 
were associated with higher abundance of Proteobacteria 
(P=0.002 and P=0.011) (Figure 6) and lower baseline abun-
dance of F. prausnitzii (P=0.02 and P=0.017), respectively, 
compared to nonoperated IBD patients and patients with 
mucosal healing.
Of the IBD patients (22 CD and 9 UC) with repeated 
microbiota analysis at follow-up 18 months after treatment, 
Figure 3 Principal component analysis, illustrating the difference in microbiota abundance of all 54 bacterial probes between IBD, non-IBD symptomatic patients, and healthy 
controls.
Notes: Each dot represents one individual. The units represent the total item loadings on each of the extracted factors.
Abbreviations: IBD, inflammatory bowel disease; PCA, principal component analysis.
Healthy
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–2 –2
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Figure 4 Sensitivity and specificity of Proteobacteria, Enterobacteriaceae, and Shigella/Escherichia abundance in differentiating Crohn’s disease phenotypes (stricturing/
penetrating vs inflammatory disease behavior) using the area under the receiver operating characteristics curve analysis.
Abbreviations: CD, Crohn’s disease; aUC, area under the curve.
Stricturing/penetrating versus inflammatory CD behavior
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Shigella/Escherichia AUC 0.75, 95% CI (0.63–0.86)
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Figure 5 Sensitivity and specificity of Firmicutes and Mycoplasma hominis abundance 
in differentiating conventional- vs biologic therapy-treated IBD patients using the 
area under the receiver operating characteristics curve analysis.
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; AUC, area 
under the curve.
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Firmicutes AUC 0.66, 95% CI (0.55–0.77)
Reference line
Figure 6 Proteobacteria abundance in iBD patients according to whether they 
needed surgery or not (measured in fluorescence signal strength in 1,000 units).
Abbreviation: IBD, inflammatory bowel disease.
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15 (48%) patients had received biologic therapy and 18 (58%) 
were in remission with mucosal healing. The microbiota 
composition and bacterial profiles were unchanged for 53 of 
54 markers after treatment, regardless of treatment modality 
received and remission status. One marker targeting Eubacte-
rium hallii species was less abundant after treatment, P=0.03.
Microbiota and association with fecal calprotectin
IBD patients with fecal calprotectin levels above 1,000 
mg/kg (31 CD, 12 UC) had significantly higher abundance 
of Proteobacteria (P=0.012) and Prevotella (P=0.011) 
than patients with lower levels (<1,000 mg/kg) of fecal 
 calprotectin (Table 2). Fecal calprotectin over 1,000 was 
associated with subsequent biologic therapy, P=0.001, but 
not with later surgery.
Discussion
In the present prospective study of newly diagnosed children 
and adolescents with IBD, we demonstrated dysbiosis in both 
treatment-naïve pediatric IBD and non-IBD symptomatic 
patients. Their fecal microbiota differed significantly from 
the microbiota of healthy children with lower bacterial abun-
dances measured with the GA-Map technology. Our non-IBD 
symptomatic patients consisted of pediatric patients admitted 
to the hospital due to symptoms and findings suspicious of 
IBD, but without evidence of inflammation during workup. 
Some of these patients may have had preclinical/latent IBD or 
other conditions such as disturbed permeability and motility 
influencing the study results. We believe most of these non-
IBD symptomatic patients have functional gastrointestinal 
disorders. Ideally we should have further characterized and 
subtyped these patients with the use of Rome criteria for 
functional gastrointestinal disorders. However, due to the 
limited sample size of 50 non-IBD symptomatic patients, 
further subclassification would reduce the statistical power 
to reveal clinical significant differences between the groups.
There was a similar dysbiotic profile with reduced micro-
bial abundance in IBD and non-IBD compared to healthy 
individuals in the present study; thus the bacterial profiles 
provided by the GA-Map technology performed less well than 
fecal calprotectin in detecting inflammation and discriminat-
ing IBD from non-IBD symptomatic patients. However, the 
finding of dysbiosis in non-IBD symptomatic patients may 
confirm the relevance of their symptoms and discomfort. 
Presence and characterization of dysbiosis enables the physi-
cian to diagnose “functional” disease in a positive manner.
Within the group of patients diagnosed with IBD, we 
found that bacterial abundances at baseline seemed to be 
associated with disease extension, phenotype, biologic 
therapy, surgery, and mucosal healing. At follow-up, after 
treatment, the dysbiosis was still present and its status mainly 
unchanged in IBD patients.
We found reduced abundances of beneficial Eubacterium 
and Bifidobacterium species in IBD and non-IBD symptom-
atic patients compared to healthy children, in agreement with 
previous adult6,19,20 and pediatric studies.21–23 Eubacteria and 
Bifidobacterium are known to inhibit the growth of potentially 
pathogenic species24 and produce short-chain fatty acids 
(SCFAs) through fermentation of dietary fiber. SCFAs are 
important energy sources for enterocytes and contribute to 
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homeostasis of colonic regulatory T cell populations.25 The 
reduction of protective commensal microbes and concomitant 
loss of their protective function can have an influence on 
development of IBD and the disease course. As expected, Bifi-
dobacterium was more abundant in healthy children below 
10 years of age than in the healthy adolescents.26 We found 
no difference in bacterial abundance between age groups for 
our IBD and non-IBD symptomatic patients. This may be 
due to disease state being a stronger driver of the microbiota 
composition than age.
Patients with IBD have an expansion of pro-inflammatory 
bacteria such as Prevotella,27,28 R. gnavus,29 and Veillon-
ella.22,28 Veillonella was enriched in our CD patients with 
upper gastrointestinal involvement. R. gnavus, a bacterium 
that expresses beta-glucuronidase activity, which may cause 
local inflammation, was associated with more extensive 
IBD distribution in our patients. Prevotella, R. gnavus, and 
Proteobacteria have been found to correlate with markers of 
disease activity and inflammation,28,30 which were reproduced 
in the present study. Proteobacteria are pathobionts, meaning 
that they may expand as a result of a microbial imbalance 
and exert pathogenic effects on the host and are consistently 
reported enriched in IBD.31–33 Our CD patients with a com-
plicated phenotype had high abundance of Proteobacteria, in 
accordance with the previous reports. Proteobacteria enrich-
ment has been associated with early relapse after induction 
of remission with exclusive enteral nutrition in pediatric 
CD,34 and in our patients, high abundance was associated 
with the need for surgery and lack of mucosal healing. These 
findings implicate that Proteobacteria abundance might be 
a marker for an aggressive disease course with a higher risk 
of treatment failure.
F. prausnitzii, a highly abundant human gut microbe, is 
reported to be reduced in both adult and pediatric patients 
with IBD.6,13,35,36 It acts as a protective factor for the intestinal 
mucosa, enhances barrier function, and can exert anti-inflam-
matory effects.20,37,38 Our IBD patients who needed surgery 
and who did not achieve mucosal healing with therapy, as 
well as patients treated with antibiotics before the IBD diag-
nosis, had the lowest abundance of F. prausnitzii. This is in 
line with observations that low abundance of F. prausnitzii 
may predict nonresponse to anti-TNF therapy in UC39 and 
relapse after infliximab termination in CD patients.40 Studies 
have found baseline microbiota to be associated with treat-
ment responses,34,36,39 but how the microbiota composition 
and abundances change with treatment is less studied. The 
IBD patients in our sample with repeated fecal microbiota 
analysis displayed persistent, unchanged dysbiosis after 
treatment, regardless of treatment modalities and remission 
status. Similar results have been reported in another pedi-
atric study, where the dysbiosis improved, but nonetheless 
persisted despite mucosal healing.41 Lewis et al found that 
effective exclusive enteral nutrition and TNF blocker therapy 
reduced but failed to eliminate the dysbiosis of pediatric CD 
patients.42 Others have found the fecal microbiota to become 
more dysbiotic with dietary treatment such as exclusive 
enteral nutrition.43–45 Perhaps sustained and deep remission 
requires normalization of the gut dysbiosis, or maybe it is not 
possible to reverse the dysbiosis once the gut homeostasis is 
perturbed as fundamentally as it is in IBD. Measuring relative 
fecal microbiota abundance might not be an optimal method 
as it is not suited to determine the effects of dysbiosis, giv-
ing no information about the functional consequences. As a 
prognostic tool, fecal microbiota profiles may still be of value, 
also in established IBD patients on treatment, as the dysbiosis 
remained despite treatment and remission. However, due to 
the small number of patients with repeated sampling, firm 
conclusions cannot be drawn.
Regarding fecal microbial differences between CD and 
UC, the literature has been conflicting. Similarly, as in our 
report, some previous studies did not find major differences 
in bacterial profiles between active CD and active UC.23,36
The strength of our study is the extensive workup, char-
acterization, and classification of our IBD patients. All non-
IBD symptomatic patients underwent the same procedures 
as the IBD patients. Upper and lower endoscopies as well as 
MRI of the small intestine were performed, and for patients 
included in the IBSEN II cohort these investigations were 
repeated after 1–2 years of follow-up. The fact that none 
of the non-IBD symptomatic patients have been diagnosed 
with IBD despite several (minimum 3, maximum 13) years 
of follow-up makes misclassifications and undiagnosed IBD 
less likely.
The healthy controls were not investigated in the same 
manner as the patients, as invasive tests in healthy children 
are considered unethical. Even though children with gastro-
intestinal complaints, recent antibiotic exposure, and elevated 
fecal calprotectin were excluded as healthy controls, some 
could have had conditions that may have influenced the study 
results, as there is substantial evidence that diseases outside 
of the gastrointestinal tract influence the gut microbiota.46
Dietary patterns and smoking are known to influence the 
microbiota;45 therefore, we excluded patients on exclusion 
diets. None of our adolescents admitted to smoking.47
The selection of microbes in the GA-map™ technology 
is based on literature studies and contain gut bacteria whose 
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profiles are known to define dysbiosis in adults, with the 
inherent risk of not including bacteria that could be impor-
tant in children and adolescents. Bacterial 16S sequencing 
of all microbes would give additional results, but is more 
expensive. The same is true for shotgun metagenomic 
sequencing, encompassing all DNA of bacteria, viruses, and 
fungi. Together with an altered bacterial composition, studies 
have revealed that IBD patients have fungal dysbiosis as well 
as alterations in the intestinal virome, which we have not 
investigated in our study.48,49 Deep sequencing and shotgun 
metagenomic sequencing methods need bioinformatics tools 
and reference datasets that are still under development and 
not yet readily available for clinical practice. The GA-Map 
technology provided us with a commercially available and 
clinically validated (in adults) tool.
Our study has several limitations. First, the sample size is 
limited, reducing the statistical power to detect differences in 
microbiota composition as statistically significant. We did not 
adjust for multiple testing as we considered this study to be 
exploratory, increasing the risk for accepting false-positive asso-
ciations. However, we validated our results by splitting our data 
into a training and a test set, and most associations estimated 
in the whole cohort remained statistically significant. The posi-
tive relationship between inflammation, increased abundance 
of pathobionts and concomitant loss of beneficial bacteria, is 
reassuring as it is in line with previous research reports.50
Another limitation is the difference in storage time of the 
fecal samples, which may have influenced outcomes. Also, 
theoretically, the representativeness of the samples could 
have deteriorated during the timespan from collection until 
frozen. Based on previous experience and in vitro examina-
tions,18 the microbial material collected in different cohorts 
was not considered to be affected. Since repeated thawing 
is known to influence the microbiota, the samples were kept 
frozen until analysis.
We acknowledge that the GA-Map technology test mea-
sures the abundance of bacteria without giving information 
about the functional importance and highly abundant bac-
teria might not be functionally active.51 Additionally, in the 
present study, we explored the fecal microbiota only. One 
study comparing mucosal associated microbiota with fecal 
microbiota reported that the ileal mucosa followed by the 
rectal mucosa obtained the best performance in classifying 
CD and that stool samples performed less well.22 Mucosa 
associated microbiota must be sampled by invasive methods. 
In this study however, we wanted noninvasive methods to 
associate microbiota with disease state. Our findings show 
promise for microbiota profiles and abundance to be used 
in conjuncture with other prognostic factors and known 
biomarkers in an attempt to risk stratify and individualize 
treatments in pediatric IBD.
Conclusion
Fecal microbiota profiles similarly differentiated IBD and 
non-IBD symptomatic children from healthy children. Micro-
biota profiles with relative enrichment of Proteobacteria and 
low abundance of F. prausnitzii in newly diagnosed pediatric 
IBD seem to be associated with complicated disease phe-
notypes, subsequent need of biologic therapy, surgery, and 
nonmucosal healing. The dysbiosis persisted after therapy, 
regardless of treatments and remission status. The relative 
abundances of selected bacteria might be of value as prog-
nostic markers in stratifying pediatric IBD into subgroups 
and aid in patient selection for early aggressive therapy in an 
effort to prevent a complicated disease course.
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Supplementary material
Table S1 List of phyla and bacterial names of the GA-Map™ technology markers
Bacteria number Phylum Name
100 actinobacteria Actinobacteria
101 actinobacteria Actinomycetales
102 actinobacteria Atopobium rimae
103 actinobacteria Bifidobacterium spp.
201 Bacteroidetes Alistipes
202 Bacteroidetes Alistipes onderdonkii
203 Bacteroidetes Bacteroides fragilis
204 Bacteroidetes Bacteroides pectinophilus
205 Bacteroidetes Bacteroides spp.
206 Bacteroidetes Bacteroides spp. and Prevotella spp.
207 Bacteroidetes Bacteroides stercoris
208 Bacteroidetes Bacteroides zoogleoformans
209 Bacteroidetes Parabacteroides johnsonii
210 Bacteroidetes Parabacteroides spp.
211 Bacteroidetes Prevotella nigrescens
300 Firmicutes Firmicutes
301 Firmicutes Anaerotruncus colihominis
302 Firmicutes Bacilli
303 Firmicutes Bacillus megaterium
304 Firmicutes Catenibacterium mitsuokai
305 Firmicutes Clostridia
306 Firmicutes Clostridium methylpentosum
307 Firmicutes Clostridium sp.
308 Firmicutes Coprobacillus cateniformis
309 Firmicutes Desulfitispora alkaliphila
310 Firmicutes Dialister invisus
311 Firmicutes Dialister invisus and Megasphaera micronuciformis
312 Firmicutes Dorea spp.
313 Firmicutes Eubacterium biforme
314 Firmicutes Eubacterium hallii
315 Firmicutes Eubacterium rectale
316 Firmicutes Eubacterium siraeum
317 Firmicutes Faecalibacterium prausnitzii
318 Firmicutes Lachnospiraceae
319 Firmicutes Lactobacillus ruminis and Pediococcus acidilactici
320 Firmicutes Lactobacillus spp.
321 Firmicutes Lactobacillus spp. 2
322 Firmicutes Phascolarctobacterium sp.
323 Firmicutes Ruminococcus albus and Ruminococcus bromii
324 Firmicutes Ruminococcus gnavus
325 Firmicutes Streptococcus agalactiae and Eubacterium rectale
326 Firmicutes Streptococcus salivarius ssp. thermophilus and sanguinis
327 Firmicutes Streptococcus salivarius ssp. thermophilus
328 Firmicutes Streptococcus spp.
329 Firmicutes Streptococcus spp. 2
330 Firmicutes Veillonella spp.
331 Firmicutes/Tenericutes/Bacteroidetes species Firmicutes (various)
500 Proteobacteria Proteobacteria
501 Proteobacteria Acinetobacter junii
502 Proteobacteria Enterobacteriaceae
503 Proteobacteria Pseudomonas spp.
504 Proteobacteria Shigella spp. and Echerichia spp.
601 Tenericutes Mycoplasma hominis
701 Verrucomicrobia Akkermansia muciniphila
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
5.
18
8.
21
6.
22
0 
on
 1
8-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical and Experimental Gastroenterology 2019:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical and Experimental Gastroenterology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal
Clinical and Experimental Gastroenterology is an international, peer-
reviewed, open access, online journal publishing original research, 
reports, editorials, reviews and commentaries on all aspects of 
gastroenterology in the clinic and laboratory. This journal is included 
on PubMed. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is all easy 
to use. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.
Dovepress
49
Olbjørn et al
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
5.
18
8.
21
6.
22
0 
on
 1
8-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
